Back to companies

Abbott Laboratories: Premium Databases

Abbott Laboratories Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Abbott Laboratories Insights data

Headline Published Journalists
Showing 3 of 130+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 27 Jun 2017 Lorem
TG Therapeutics’ GENUINE CLL trial data supportive of accelerated approval despite protocol amendment concerns – experts 28 Mar 2017 Alaric DeArment
AbbVie/Roche's Venclexta has solid backing for Rituxan combination in CLL, positive Phase III trial – experts 17 Mar 2017 Alaric DeArment
AstraZeneca’s durvalumab/tremelimumab Phase III NSCLC dosing regimen should boost safety profile though toxicity caution remains - experts 16 Feb 2017 Hamish McDougall


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer